Literature DB >> 20127033

Dual role of complement in tumour growth and metastasis (Review).

Cordula Stover1.   

Abstract

Complement-dependent cytotoxicity is one of the mechanisms by which therapeutic monoclonal antibodies are successful against cancer. Complement is one of the innate immune defence systems, whose activation products and membrane-bound regulators interact with cells of the adaptive immune response. The complement system is currently undergoing a re-appreciation in its role within the immune surveillance of tumour. The majority of human tumours are low immunogenic. Complement may be involved through direct, 'danger signal'-elicited activation or via infiltration of inflammatory cells, which express complement components. Inflammatory cells may be associated with malignant transformation and tumour regression. The evidence for the effects of complement activation and regulation on tumour progression and expansion will be reviewed using in vivo, in vitro, and patient studies, and conclusions drawn for the implications in therapy and management of tumour patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127033     DOI: 10.3892/ijmm_00000346

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  13 in total

1.  Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1.

Authors:  George S Karagiannis; Aaron Berk; Apostolos Dimitromanolakis; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2013-04-18       Impact factor: 6.603

Review 2.  Complement: an overview for the clinician.

Authors:  Juan Carlos Varela; Stephen Tomlinson
Journal:  Hematol Oncol Clin North Am       Date:  2015-04-04       Impact factor: 3.722

3.  The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis.

Authors:  Silvio Bandini; Marco Macagno; Albana Hysi; Stefania Lanzardo; Laura Conti; Amanda Bello; Federica Riccardo; Roberto Ruiu; Irene Fiore Merighi; Guido Forni; Manuela Iezzi; Elena Quaglino; Federica Cavallo
Journal:  Oncoimmunology       Date:  2016-11-08       Impact factor: 8.110

Review 4.  Nanoparticle personalized biomolecular corona: implications of pre-existing conditions for immunomodulation and cancer.

Authors:  Jacob Shaw; Ryan M Pearson
Journal:  Biomater Sci       Date:  2022-05-17       Impact factor: 7.590

Review 5.  Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.

Authors:  Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Jacob Danoff; Hassan Madani; Adam Sugarman; Florin Niculescu; Petru A Mircea; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

Review 6.  The overlapping roles of antimicrobial peptides and complement in recruitment and activation of tumor-associated inflammatory cells.

Authors:  Izzat A M Al-Rayahi; Raghad H H Sanyi
Journal:  Front Immunol       Date:  2015-01-22       Impact factor: 7.561

7.  The human complement inhibitor Sushi Domain-Containing Protein 4 (SUSD4) expression in tumor cells and infiltrating T cells is associated with better prognosis of breast cancer patients.

Authors:  Emelie Englund; Bart Reitsma; Ben C King; Astrid Escudero-Esparza; Sioned Owen; Akira Orimo; Marcin Okroj; Lola Anagnostaki; Wen G Jiang; Karin Jirström; Anna M Blom
Journal:  BMC Cancer       Date:  2015-10-19       Impact factor: 4.430

8.  Tumour cell conditioned medium reveals greater M2 skewing of macrophages in the absence of properdin.

Authors:  Izzat A M Al-Rayahi; Michael J Browning; Cordula Stover
Journal:  Immun Inflamm Dis       Date:  2017-01-26

9.  Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice.

Authors:  Silvio Bandini; Claudia Curcio; Marco Macagno; Elena Quaglino; Maddalena Arigoni; Stefania Lanzardo; Albana Hysi; Giuseppina Barutello; Lorena Consolino; Dario Livio Longo; Piero Musiani; Guido Forni; Manuela Iezzi; Federica Cavallo
Journal:  Oncoimmunology       Date:  2013-09-12       Impact factor: 8.110

10.  C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation.

Authors:  Roberta Bulla; Claudio Tripodo; Damiano Rami; Guang Sheng Ling; Chiara Agostinis; Carla Guarnotta; Sonia Zorzet; Paolo Durigutto; Marina Botto; Francesco Tedesco
Journal:  Nat Commun       Date:  2016-02-01       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.